IRIS
LA MONICA, Silvia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.527
AS - Asia 4.746
EU - Europa 3.814
SA - Sud America 662
AF - Africa 279
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 4
Totale 15.043
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.412
SG - Singapore 1.645
CN - Cina 1.370
IT - Italia 996
VN - Vietnam 783
IE - Irlanda 574
SE - Svezia 534
BR - Brasile 512
FI - Finlandia 422
DE - Germania 348
HK - Hong Kong 346
FR - Francia 187
ZA - Sudafrica 160
UA - Ucraina 155
NL - Olanda 149
GB - Regno Unito 117
IN - India 114
TR - Turchia 109
RU - Federazione Russa 82
CA - Canada 70
AT - Austria 65
CI - Costa d'Avorio 62
AR - Argentina 60
BE - Belgio 47
JP - Giappone 42
BD - Bangladesh 40
ID - Indonesia 36
IQ - Iraq 32
KR - Corea 32
PL - Polonia 32
MX - Messico 26
CO - Colombia 25
ES - Italia 25
PK - Pakistan 25
PH - Filippine 24
EC - Ecuador 22
CZ - Repubblica Ceca 19
TH - Thailandia 19
SA - Arabia Saudita 15
MA - Marocco 14
IR - Iran 13
UZ - Uzbekistan 13
KE - Kenya 11
LT - Lituania 11
VE - Venezuela 11
CL - Cile 10
HU - Ungheria 9
MY - Malesia 8
AU - Australia 7
JO - Giordania 7
PY - Paraguay 7
SY - Repubblica araba siriana 7
TN - Tunisia 7
TW - Taiwan 7
AL - Albania 6
DZ - Algeria 6
LU - Lussemburgo 6
NP - Nepal 6
PS - Palestinian Territory 6
UY - Uruguay 6
AZ - Azerbaigian 5
BO - Bolivia 5
EG - Egitto 5
KG - Kirghizistan 5
OM - Oman 5
RO - Romania 5
CH - Svizzera 4
IL - Israele 4
NZ - Nuova Zelanda 4
PE - Perù 4
AE - Emirati Arabi Uniti 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GE - Georgia 3
JM - Giamaica 3
KZ - Kazakistan 3
LB - Libano 3
MD - Moldavia 3
PA - Panama 3
SI - Slovenia 3
BB - Barbados 2
CR - Costa Rica 2
CY - Cipro 2
DK - Danimarca 2
EU - Europa 2
GA - Gabon 2
GT - Guatemala 2
HR - Croazia 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
QA - Qatar 2
RS - Serbia 2
SN - Senegal 2
TJ - Tagikistan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AD - Andorra 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
Totale 15.023
Salva come PNG Salva come JPEG
Città #
Singapore 876
Dallas 616
Ashburn 613
Dublin 572
Chandler 499
San Jose 419
Hong Kong 321
Santa Clara 321
Beijing 317
Ann Arbor 314
Parma 313
Ho Chi Minh City 231
Jacksonville 186
Boardman 179
Dearborn 167
Hanoi 154
Johannesburg 152
Los Angeles 142
Nanjing 119
Shanghai 115
Munich 107
Chicago 104
New York 104
Lauterbourg 98
Princeton 89
Hefei 87
Milan 83
Izmir 82
Abidjan 62
Council Bluffs 58
Wilmington 57
Bremen 56
San Mateo 55
Nanchang 51
São Paulo 51
Vienna 50
Kunming 48
Helsinki 47
Shenyang 47
Buffalo 42
Bologna 41
Haiphong 40
Tianjin 38
Marseille 35
Toronto 34
Brussels 30
Columbus 29
Da Nang 29
Des Moines 29
Guangzhou 29
Hebei 29
Jinan 29
Jakarta 28
Moscow 28
Seattle 27
Turku 26
Modena 25
Warsaw 25
London 24
Rome 24
Tokyo 24
Frankfurt am Main 23
Pune 23
The Dalles 23
Denver 22
Changsha 21
Grafing 21
Nuremberg 21
Woodbridge 21
Amsterdam 20
Seoul 20
Norwalk 19
Redmond 19
Reggio Emilia 19
Rio de Janeiro 19
Phoenix 18
Jiaxing 17
Stockholm 17
Brooklyn 16
Houston 16
Atlanta 15
Fremont 15
Manchester 14
Orem 14
Brasília 13
Chennai 13
Hải Dương 13
Leawood 13
Montreal 13
Boston 12
Brescia 12
Tashkent 12
Wayne 12
Baghdad 11
Bari 11
Belo Horizonte 11
Biên Hòa 11
New Delhi 11
Poplar 11
San Francisco 11
Totale 9.250
Salva come PNG Salva come JPEG
Nome #
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 273
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 258
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 246
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 242
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 239
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 210
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 210
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 204
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 202
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 198
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 193
Characterization of gefitinib uptake in NSCLC cell lines 189
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 189
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 188
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 185
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 182
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 180
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 179
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 179
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 178
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 177
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 176
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 176
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 176
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 173
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 173
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 172
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 169
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 168
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 168
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 167
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 166
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 165
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 163
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 160
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 158
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 157
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 157
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 156
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 156
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 155
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 154
155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 154
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 152
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 151
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes 147
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 145
Physico-chemical characterization and biological evaluation of two fibroin materials 144
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 144
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 144
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 139
Interaction between Occupational and Non-Occupational Arsenic Exposure and Tobacco Smoke on Lung Cancerogenesis: A Systematic Review 138
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 136
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 132
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 131
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 130
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 126
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 126
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation 125
Interaction between occupational radon exposure and tobacco smoke: a systematic review 124
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 124
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 123
Down-Modulation of Erk Protein Kinase Activity Inhibits Vascular Endothelial Growth Factor (VEGF) Secretion by human Myeloma Cell Lines 121
PD-L1 level is up-regulated in NSCLC cells after pemetrexed treatment 120
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 120
Successful regrowth of retinal neurons when cultured interfaced to carbon nanotube platforms 117
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones 117
VASCULAR ENDOTHELIAL GROWTH FACTOR SECRETION BY MYELOMA CELLS IS INHIBITED BY DOWN-MODULATING ERK PROTEIN KINASE ACTIVITY 115
Osteopontin is produced by human multiple myeloma cells 115
Correction to: Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer (Cancers, (2020), 12, 3, (666), 10.3390/cancers12030666) 114
Multiple myeloma patient with unusual extramedullary involvement 114
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease 114
Role of cell gefitinib metabolism in the response of NSCLC cell lines to gefitinib. 113
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 110
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer 109
Synergistic effect of PI3K and FAK inhibition in squamous lung cancer cells with reduced PTEN level 109
Amino acid signaling through the mammalian target of rapamycin (mTOR) pathway: Role of glutamine and of cell shrinkage 109
Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry 108
Multiple myeloma patient with unusual extramedullary involvement 107
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 106
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines 106
Correction to: The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells (Journal of Experimental & Clinical Cancer Research, (2018), 37, 1, (72), 10.1186/s13046-018-0741-3) 105
Synergistic activity of letrozole and sorafenib on breast cancer cells 105
The maintenance of gefitinib inhibits migration and epithelial-mesenchimal transition of Non-small cell lung cancer cell lines that have become resistant after prolonged gefitinib treatment 104
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines 103
Inhibition of Human Malignant Pleural Mesothelioma Growth by Mesenchymal Stromal Cells 102
Effect of letrozole and sorafenib on cell proliferation and apoptosis of MCF-7/AROM-1 breast cancer cell line 99
Synergic anti-proliferative effect of gefitinib and RAD001 in non small cell lung cancer cell lines 99
Generation and characterization of a new preclinical mouse model of egfr-driven lung cancer with met-induced osimertinib resistance 98
Targeting FGFR1 pathway in squamous cell lung cancer 96
Optimizing EGFR inhibitor treatment in non small cell lung cancer 95
Overcoming resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer cell lines 95
Erlotinib potentiates Cetuximab-dependent call citotoxicity in EGFR wild type NSCLC cell lines 93
Preclinical study assessing effects of gefitinib continuation after development of gefitinib resistance in NSCLC with activating EGFR mutations 90
Evaluation of gefitinib maintenance in an EGFR-mutant NSCLC cell line with acquired resistance 89
RANKL is critically involved in the physiopathology of multiple myeloma 89
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 88
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review 88
RANKL is critically involved in the physiopathology of multiple myeloma 86
Circulating neural growth factor in pancreatic cancer adenocarcinoma 85
Totale 14.454
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.094
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.094
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021213 0 0 0 0 0 0 0 0 0 26 135 52
2021/2022574 36 15 52 41 20 25 88 50 31 22 40 154
2022/20232.208 211 234 150 141 197 244 45 142 687 17 101 39
2023/20241.003 35 73 34 47 81 185 85 81 44 55 105 178
2024/20252.898 137 136 185 197 279 281 204 144 338 241 261 495
2025/20265.875 517 583 853 585 815 354 690 200 893 385 0 0
Totale 15.234